 BEVERLY HILLS, Calif., June 23, 2021 PRNewswire -- GT Biopharma, Inc. NASDAQ: GTBP, a clinical stage immuno-oncology company focused on developing innovative therapeutics based on the Companys proprietary NK cell engager TriKETM protein biologic technology platform, announced Jeffrey S. 